ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells

Xu,Yunjie; Gao,Weinan; Zhang,Yong; Wu,Shanshan; Liu,Yanan; Deng,Xinyue; Xie,Lili; Yang,Jiayan; Yu,Huimei; Su,Jing; Sun,Liankun

doi:10.3892/ijo.2018.4476

ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells

Authors:
- Yunjie Xu
- Weinan Gao
- Yong Zhang
- Shanshan Wu
- Yanan Liu
- Xinyue Deng
- Lili Xie
- Jiayan Yang
- Huimei Yu
- Jing Su
- Liankun Sun
View Affiliations

Affiliations: Department of Pathophysiology, Basic College of Medicine, Jilin University, Changchun, Jilin 130021, P.R. China, School of Clinical Medicine, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Oral Geriatrics, School and Hospital of Stomatology, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: July 9, 2018 https://doi.org/10.3892/ijo.2018.4476
Pages: 1055-1068
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The poor prognosis and high mortality of patients with ovarian cancer result in part from their poor response to platinum-based chemotherapy. However, the precise mechanism behind cisplatin resistance is still not fully understood. In the present study, the authors explored the mechanism of resistance to cisplatin from the perspective of glucose metabolism in human ovarian cancer. The experiments using genetically matched ovarian cancer cell lines SKOV3 (cisplatin-sensitive) and SKOV3/DDP (cisplatin-resistant) in the present study provided some important findings. First, in comparison to SKOV3 cells, SKOV3/DDP cells exhibited decreased dependence on aerobic glycolysis and an increased demand for glucose. Secondly, the stable overexpression of Bcl‑2 and ability to shift metabolism towards oxidative phosphorylation (OXPHOS) in SKOV3/DDP cells were associated with increased oxygen consumption. Furthermore, the metabolic characteristic of elevated OXPHOS primarily comprised most mitochondrial‑derived reactive oxygen species (ROS) and, at least in part, contributed to the slight pro-oxidant state of SKOV3/DDP cells in turn. Thirdly, SKOV3/DDP cells reset the redox balance by overexpressing the key enzyme glucose 6-phosphate dehydrogenase (G6PD) of the pentose phosphate pathway to eliminate the cytotoxicity of highly elevated ROS. Furthermore, the inhibition of Bcl‑2 reduced the OXPHOS and sensitivity of SKOV3/DDP cells to cisplatin in a selective manner. Furthermore, when combined with 2-deoxyglucose (2-DG), the anticancer effect of the Bcl‑2 inhibitor ABT737 was greatly potentiated and hypoxia-inducible factor 1α (HIF‑1α) appeared to be closely associated with Bcl‑2 family members in the regulation of glucose metabolism. These results suggested that the special glucose metabolism in SKOV3/DDP cells might be selectively targeted by disrupting Bcl‑2-dependent OXPHOS.

View Figures

View References

1	Tew WP and Fleming GF: Treatment of ovarian cancer in the older woman. Gynecol Oncol. 136:136–142. 2015. View Article : Google Scholar
2	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
3	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
4	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer. 47:1585–1594. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ma L, Xu Y, Su J, Yu H, Kang J, Li H, Li X, Xie Q, Yu C, Sun L, et al: Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. Int J Oncol. 47:1890–1900. 2015. View Article : Google Scholar : PubMed/NCBI
7	Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y and Sun L: ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca²⁺ signal transduction in human ovarian cancer cells. Int J Oncol. 49:2507–2519. 2016. View Article : Google Scholar : PubMed/NCBI
8	Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, et al: BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 12:329–341. 2013. View Article : Google Scholar : PubMed/NCBI
9	Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
10	Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, et al: BCL-xL: Time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death Differ. 13:1156–1169. 2006. View Article : Google Scholar
11	Bae IH, Yoon SH, Lee SB, Park JK, Ho JN and Um HD: Signaling components involved in Bcl-w-induced migration of gastric cancer cells. Cancer Lett. 277:22–28. 2009. View Article : Google Scholar
12	Kelekar A and Thompson CB: Bcl-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol. 8:324–330. 1998. View Article : Google Scholar : PubMed/NCBI
13	Manfredi G, Kwong JQ, Oca-Cossio JA, Woischnik M, Gajewski CD, Martushova K, D'Aurelio M, Friedlich AL and Moraes CT: BCL-2 improves oxidative phosphorylation and modulates adenine nucleotide translocation in mitochondria of cells harboring mutant mtDNA. J Biol Chem. 278:5639–5645. 2003. View Article : Google Scholar
14	Dey R and Moraes CT: Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem. 275:7087–7094. 2000. View Article : Google Scholar : PubMed/NCBI
15	Warburg O: Iron, the oxygen-carrier of respiration-ferment. Science. 61:575–582. 1925. View Article : Google Scholar : PubMed/NCBI
16	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
17	Chandel NS: Mitochondria and cancer. Cancer Metab. 2:82014. View Article : Google Scholar : PubMed/NCBI
18	Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, et al: Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 23:1542–1554. 2016. View Article : Google Scholar : PubMed/NCBI
19	Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, Giannoni E, Schrader T, Puhr M, Chiarugi P, et al: Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget. 7:61890–61904. 2016. View Article : Google Scholar : PubMed/NCBI
20	Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, et al: 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. 6:41706–41721. 2015. View Article : Google Scholar : PubMed/NCBI
21	Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, Mammi S and Caparrotta L: 'Metabolic reprogramming' in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets. 11:226–235. 2011. View Article : Google Scholar
22	Fan Z, Yu H, Cui N, Kong X, Liu X, Chang Y, Wu Y, Sun L and Wang G: ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. Exp Cell Res. 335:68–81. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Bol V, Bol A, Bouzin C, Labar D, Lee JA, Janssens G, Porporato PE, Sonveaux P, Feron O and Grégoire V: Reprogramming of tumor metabolism by targeting mitochondria improves tumor response to irradiation. Acta Oncol. 54:266–274. 2015. View Article : Google Scholar
25	Xiang XY, Kang JS, Yang XC, Su J, Wu Y, Yan XY, Xue YN, Xu Y, Liu YH, Yu CY, et al: SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells. Int J Oncol. 49:773–784. 2016. View Article : Google Scholar : PubMed/NCBI
26	Floreani M, Petrone M, Debetto P and Palatini P: A comparison between different methods for the determination of reduced and oxidized glutathione in mammalian tissues. Free Radic Res. 26:449–455. 1997. View Article : Google Scholar : PubMed/NCBI
27	Deberardinis RJ, Sayed N, Ditsworth D and Thompson CB: Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev. 18:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
28	Caneba CA, Yang L, Baddour J, Curtis R, Win J, Hartig S, Marini J and Nagrath D: Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells. Cell Death Dis. 5:e13022014. View Article : Google Scholar : PubMed/NCBI
29	Stanton RC: Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 64:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
30	Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
31	Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci. 39:347–354. 2014. View Article : Google Scholar : PubMed/NCBI
32	Köhler E, Barrach H and Neubert D: Inhibition of NADP dependent oxidoreductases by the 6-aminonicotinamide analogue of NADP. FEBS Lett. 6:225–228. 1970. View Article : Google Scholar : PubMed/NCBI
33	Raineri R and Levy HR: On the specificity of steroid interaction with mammary glucose 6-phosphate dehydrogenase. Biochemistry. 9:2233–2243. 1970. View Article : Google Scholar : PubMed/NCBI
34	Gross A: BCL-2 family proteins as regulators of mitochondria metabolism. Biochim Biophys Acta. 1857.1243–1246. 2016.
35	Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, et al: Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 22:547–560. 2012. View Article : Google Scholar : PubMed/NCBI
36	Weinberg SE and Chandel NS: Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 11:9–15. 2015. View Article : Google Scholar :
37	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
38	Berridge MV, Herst PM and Tan AS: Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion. 10:584–588. 2010. View Article : Google Scholar : PubMed/NCBI
39	Jose C, Hébert-Chatelain E, Bellance N, Larendra A, Su M, Nouette-Gaulain K and Rossignol R: AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta. 1807.707–718. 2011.
40	Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, et al: Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 23:811–825. 2013. View Article : Google Scholar : PubMed/NCBI
41	Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, et al: Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 329:1492–1499. 2010. View Article : Google Scholar : PubMed/NCBI
42	Ahn CS and Metallo CM: Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 3:12015. View Article : Google Scholar : PubMed/NCBI
43	Vander Heiden MG: Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov. 10:671–684. 2011. View Article : Google Scholar : PubMed/NCBI
44	Lee YJ, Galoforo SS, Berns CM, Tong WP, Kim HR and Corry PM: Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: Role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci. 110:681–686. 1997.PubMed/NCBI
45	Catanzaro D, Gaude E, Orso G, Giordano C, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C and Montopoli M: Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget. 6:30102–30114. 2015. View Article : Google Scholar : PubMed/NCBI
46	Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW, Liu P and Wei W: The two faces of FBW7 in cancer drug resistance. BioEssays. 33:851–859. 2011. View Article : Google Scholar : PubMed/NCBI
47	Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
48	Sengupta N, Rose ST and Morgan JA: Metabolic flux analysis of CHO cell metabolism in the late non-growth phase. Biotechnol Bioeng. 108:82–92. 2011. View Article : Google Scholar
49	Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A and Ghigo D: Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J. 439:141–149. 2011. View Article : Google Scholar : PubMed/NCBI
50	Wang J, Yuan W and Chen Z, Wu S, Chen J, Ge J, Hou F and Chen Z: Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol. 33:95–101. 2012. View Article : Google Scholar
51	Clément MV, Hirpara JL and Pervaiz S: Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ. 10:1273–1285. 2003. View Article : Google Scholar : PubMed/NCBI
52	Chen ZX and Pervaiz S: Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ. 14:1617–1627. 2007. View Article : Google Scholar : PubMed/NCBI
53	Chen ZX and Pervaiz S: Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ. 17:408–420. 2010. View Article : Google Scholar
54	Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 17:393–403. 2005. View Article : Google Scholar : PubMed/NCBI
55	Dai Y, Jin S, Li X and Wang D: The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget. 8:1354–1368. 2017.
56	Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010. View Article : Google Scholar :
57	Wang GL and Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 90:4304–4308. 1993. View Article : Google Scholar : PubMed/NCBI
58	Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634. 2010. View Article : Google Scholar :
59	Ai Z, Lu Y, Qiu S and Fan Z: Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016. View Article : Google Scholar : PubMed/NCBI